Download PDF
Klin Monbl Augenheilkd 2018; 235(06): 721-724
DOI: 10.1055/s-0042-122339
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Botulinumtoxintherapie – neue Entwicklungen in der Augenheilkunde

Botulinum Toxin – New Developments in Ophthalmology
B. Wabbels
Orthoptik und Neuro-Ophthalmologie, Universitäts-Augenklinik, Bonn
› Author Affiliations
Further Information

Publication History

eingereicht 04 November 2016

akzeptiert 21 November 2016

Publication Date:
23 January 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Botulinumtoxin ist seit Jahren der Goldstandard bei der Behandlung des essenziellen Blepharospasmus und des Hemispasmus facialis, ähnlich wirksam bei Synkinesien nach Fazialisparese. Falls für den individuellen Patienten erforderlich, können die Injektionsintervalle bei Lidkrämpfen auf bis zu 6 Wochen verkürzt werden. Neuere Indikationen in der Augenheilkunde umfassen die Lidretraktion bei endokriner Orbitopathie, die Induktion einer protektiven Ptosis und die Behandlung von Krokodilstränen. Zukünftig kommt Botulinumtoxin evtl. auch zur Behandlung von Depressionen (facial feedback), von Wunden im Gesichtsbereich und zum Schutz von Drüsen vor Bestrahlungsfolgen in Betracht.

Abstract

Botulinum toxin is recognised as the gold standard for the treatment of essential blepharospasm and hemifacial spasm, which is similar in effect in synkinesis after facial nerve palsy. The injection intervals can be adjusted according to the patientsʼ needs and be shortened for up to six weeks in cases of eyelid cramping. Newer indications for the use of botulinum toxin in ophthalmology include eyelid retraction in Gravesʼ disease, induction of protective ptosis and treatment of crocodile tears syndrome after facial nerve palsy. In future, botulinum toxin may be used in depression (facial feedback), facial injuries and for protection of facial glands against irradiation injury.

Schlüsselwörter

Neuroophthalmologie - Botulinumtoxin - verkürzte Intervalle - Synkinesien - endokrine Orbitopathie - Krokodilstränen

Key words

neuroophthalmology - botulinum toxin - shorter intervals - synkinesia - Gravesʼ disease - crocodile tears
 

  • Literatur

  • 1 Roggenkämper P, Laskawi R. Essenzieller Blepharospasmus. In: Laskawi R, Roggenkämper P. Hrsg. Botulinumtoxin – Therapie im Kopf-Hals-Bereich. 2. Aufl.. München: Urban & Vogel; 2004: 73-89
    Google Scholar
  • 2 Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87: 1044-1049
    CrossrefPubMedGoogle Scholar
  • 3 Roggenkämper P. Blepharospasmus-Behandlung mit Botulinus-Toxin (Verlaufsbeobachtungen). Klin Monatsbl Augenheilkd 1986; 189: 283-285
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Wabbels B, Roggenkämper P. Essenzieller Blepharospasmus: Praxisnahe Therapie mit Botulinumtoxin unter Verwendung verkürzter Behandlungsintervalle. Ophthalmologe 2012; 109: 45-53
    CrossrefPubMedGoogle Scholar
  • 5 Evidente VG, Truong D, Jankovic J. et al. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. J Neurol Sci 2014; 346: 116-120
    CrossrefPubMedGoogle Scholar
  • 6 Wickwar S, McBain H, Newman SP. et al. Erratum to: ‘Effectiveness and cost-effectiveness of a patient-initiated botulinum toxin treatment model for blepharospasm and hemifacial spasm compared to standard care: study protocol for a randomised controlled trial’. Trials 2016; 17: 333
    CrossrefPubMedGoogle Scholar
  • 7 Wickwar S, McBain H, Newman SP. et al. Effectiveness and cost-effectiveness of a patient-initiated botulinum toxin treatment model for blepharospasm and hemifacial spasm compared to standard care: study protocol for a randomised controlled trial. Trials 2016; 17: 129
    CrossrefPubMedGoogle Scholar
  • 8 Wabbels B. Botulinum toxin therapy in congenital blepharospasm. Case Rep Ophthalmol 2014; 5: 435-438
    CrossrefPubMedGoogle Scholar
  • 9 Wabbels B, Förl M. Botulinumtoxin bei Überfunktion der Tränendrüse, spastischem Entropium und Oberlidretraktion bei endokriner Orbitopathie. Ophthalmologe 2007; 104: 771-776
    CrossrefPubMedGoogle Scholar
  • 10 Merte RL, Lanzl IM. Botulinumtoxin-Injektionen zur Erzeugung einer Ptosis. Ophthalmologe 2007; 104: 767-770
    CrossrefPubMedGoogle Scholar
  • 11 Gassner HG, Brissett AE, Otley CC. et al. Botulinum toxin to improve facial wound healing: a prospective, blinded, placebo-controlled study. Mayo Clin Proc 2006; 81: 1023-1028
    CrossrefPubMedGoogle Scholar
  • 12 Ziade M, Domergue S, Batifol D. et al. Use of botulinum toxin type A to improve treatment of facial wounds: a prospective randomised study. J Plast Reconstr Aesthet Surg 2013; 66: 209-214
    CrossrefPubMedGoogle Scholar
  • 13 Freshwater MF. Botulinum toxin for scars: can it work, does it work, is it worth it?. J Plast Reconstr Aesthet Surg 2013; 66: e92-e93
    CrossrefPubMedGoogle Scholar
  • 14 Kim YS, Lee HJ, Cho SH. et al. Early postoperative treatment of thyroidectomy scars using botulinum toxin: a split-scar, double-blind randomized controlled trial. Wound Repair Regen 2014; 22: 605-612
    CrossrefPubMedGoogle Scholar
  • 15 Dodick DW, Turkel CC, DeGryse RE. et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50: 921-936
    CrossrefPubMedGoogle Scholar
  • 16 Aurora SK, Winner P, Freeman MC. et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011; 51: 1358-1373
    CrossrefPubMedGoogle Scholar
  • 17 Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA 2012; 307: 1736-1745
    CrossrefPubMedGoogle Scholar
  • 18 Zajonc RB. Emotion and facial efference: a theory reclaimed. Science 1985; 228: 15-21
    CrossrefPubMedGoogle Scholar
  • 19 Parsaik AK, Mascarenhas SS, Hashmi A. et al. Role of botulinum toxin in depression. J Psychiatr Pract 2016; 22: 99-110
    CrossrefPubMedGoogle Scholar
  • 20 Ochudlo S, Bryniarski P, Opala G. Botulinum toxin improves the quality of life and reduces the intensification of depressive symptoms in patients with blepharospasm. Parkinsonism Relat Disord 2007; 13: 505-508
    CrossrefPubMedGoogle Scholar
  • 21 Rohrbach S, Junghans K, Köhler S. et al. Minimally invasive application of botulinum toxin A in patients with idiopathic rhinitis. Head Face Med 2009; 5: 18
    CrossrefPubMedGoogle Scholar
  • 22 Iannitti T, Palmieri B, Aspiro A. et al. A preliminary study of painless and effective transdermal botulinum toxin A delivery by jet nebulization for treatment of primary hyperhidrosis. Drug Des Devel Ther 2014; 8: 931-935
    PubMedGoogle Scholar
  • 23 Teymoortash A, Müller F, Juricko J. et al. Botulinum toxin prevents radiotherapy-induced salivary gland damage. Oral Oncol 2009; 45: 737-739
    CrossrefPubMedGoogle Scholar